CWA Asset Management Group LLC Invests in Johnson & Johnson

CWA Asset Management Group LLC has made a significant investment in Johnson & Johnson (NYSE:JNJ) during the third quarter, as indicated in its latest Form 13F filing with the Securities and Exchange Commission. The firm acquired 135,305 shares of Johnson & Johnson, which are valued at around $21,927,000. This investment represents approximately 1.2% of CWA Asset Management Group LLC's total holdings, positioning Johnson & Johnson as the 15th largest holding in its portfolio.

Several other institutional investors have also made adjustments regarding their stakes in Johnson & Johnson. For example, Meridian Financial Partners LLC bought a new position earlier in the second quarter, investing about $1,626,000. Additionally, Lmcg Investments LLC increased its stake in Johnson & Johnson by 32.7% during the third quarter, holding now 87,162 shares valued at $14,125,000 after purchasing an additional 21,471 shares. NTV Asset Management LLC and Cooper Haims Advisors LLC also boosted their stakes, owning 36,000 and 3,358 shares, respectively. Overall, about 69.55% of Johnson & Johnson’s stock is currently held by institutional investors.

Insider Activity

In related news concerning Johnson & Johnson, Vice President Robert J. Decker sold 5,635 shares on August 30th. The shares were sold at an average price of $165.06, totaling approximately $930,113. This transaction slightly reduced his ownership, as he now holds 18,973 shares valued at around $3,131,683.38. Currently, company insiders possess about 0.16% of the stock.

Stock Performance

On the trading front, Johnson & Johnson's shares opened at $155.62. The company boasts a market capitalization of $374.67 billion and has a price-to-earnings ratio of 22.52. This stock also has a 12-month low of $143.13 and a high of $168.85, indicating some variability in its performance. Recently, the firm reported its earnings for the last quarter, revealing earnings per share (EPS) of $2.42, which surpassed the consensus estimate of $2.21. Their revenue was reported at $22.47 billion, exceeding estimates of $22.17 billion.

Dividend Information

The company has also declared a quarterly dividend of $1.24 per share, payable on December 10th to shareholders on record by November 26th. This results in an annual dividend yield of 3.19%, with a payout ratio of 71.78%.

Analyst Ratings and Predictions

Brokerage firms have been adjusting their price targets for Johnson & Johnson. Goldman Sachs reduced their target from $160.00 to $155.00, while Citigroup increased theirs to $185.00 from $180.00. Overall, analysts have divided opinions on the stock, with several recommending a hold or buy rating. The consensus rating stands as a “Moderate Buy” with a price target averaging around $175.00.

About Johnson & Johnson

Johnson & Johnson, along with its subsidiaries, focuses on the research, development, manufacturing, and selling of various healthcare products globally. Their Innovative Medicine segment covers a wide range of therapeutic areas, indicating the company's influential presence in the healthcare industry.

investment, stocks, healthcare